Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • BI 2536 - Lymphoma, Non-Hodgkin
    Clinical Study Number 1216.3
    Study Indication Lymphoma, Non-Hodgkin
    Product BI 2536
    Generic Name BI 2536
    Lab Code
    Clinical Phase I
    Study Title

    An open Phase I single dose escalation study of BI 2536 administered intravenously in patients with refractory or relapsed non-Hodgkin’s lymphoma

    Study Document
    Trial synopsis 1216.3_CO english
  • BI 695500 - Lymphoma, Non-Hodgkin
    Clinical Study Number 1301.6
    Study Indication Lymphoma, Non-Hodgkin
    Product BI 695500
    Generic Name BI 695500
    Lab Code
    Clinical Phase III
    Study Title

    A Phase III, randomized, double-blind, multi-center, multi-national trial to evaluate efficacy and safety of BI 695500 versus rituximab as a first-line immunotherapy treatment in patients with low tumor burden follicular lymphoma

    Study Document
    Trial statement 1301.6_DR english
    Trial synopsis 1301.6_DR english
  • BI 695500 - Coronary Artery Disease , Lymphoma, Non-Hodgkin
    Clinical Study Number 1301.2
    Study Indication Coronary Artery Disease ; Lymphoma, Non-Hodgkin
    Product BI 695500
    Generic Name BI 695500
    Lab Code BI 695500
    Clinical Phase III
    Study Title

    A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated follicular non- Hodgkin’s lymphoma

    Study Document
    Trial statement 1301.2 english